Business Description
Zenith Capital Corp., formerly Zenith Epigenetics Corp., is a Canadian biotechnology investment firm founded in 2013 and based in Calgary. The company focuses on developing bromodomain inhibitors to treat cancer and other serious diseases where effective treatments remain limited. Its primary drug candidate, ZEN-3694, is currently in Phase 2 clinical trials for two forms of cancer ? metastatic castration-resistant prostate cancer and advanced triple-negative breast cancer ? through partnerships with Astellas, Newsoara, and Pfizer. The company also works alongside the National Cancer Institute on research and development efforts.